Skip to content
Screener

Cytokinetics CYTK Total Operating Expenses

Total Operating Expenses at other companies

Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$54.12M+17.7%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$36.77M+47.2%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$57.38M+37.6%
iRhythm Holdings, Inc. logo
iRhythm Holdings, Inc.IRTC
$165.75M+9.4%
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$45.34M+2.0%
Boston Scientific logo
Boston ScientificBSX
$2.51B+9.8%

Other financials

Income statement

See full
Revenue$28.6M-57.1%
Operating income-$179.2M-60.7%
Net income-$198.8M-47.9%
EPS (diluted)-$1.50-33.9%

Balance sheet

See full
Cash & equivalents$255.3M+241%
Total debt$399.0M+31.2%
Total equity-$173.5M+52.9%
Total assets$1.9B+57.0%

Cash flow

See full
Operating cash flow-$159.8M-24.6%
CapEx$4.3M+4.6%
Free cash flow-$164.2M-24.0%

Valuation

See full
Market cap$10.71B+155%
Enterprise value$10.85B+145%
P/S158.2×+109×

Profitability

See full
Operating margin-1,046.1%+1,858pp
Net margin-1,321.1%+8,702pp
FCF margin-858.2%+1,799pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio6.7×-0.1×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338217
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Selling, general and administrative104,39765,721209,293123,090
Cost of goods sold2,7312,891
Collaboration cost of revenues2,8612,4165,2533,995
Total operating expenses207,796178,275410,769335,485
Operating loss(179,172)(111,506)(362,790)(267,137)
Interest and other expense, net(14,654)(11,084)(29,173)(19,952)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements(20,177)(13,181)(38,993)(27,259)
Interest and other income, net13,94113,00124,96326,702

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Cytokinetics's total operating expenses?
Cytokinetics (CYTK) reported total operating expenses of $207.8M in Q2 2026.
How has Cytokinetics's total operating expenses changed year-over-year?
Cytokinetics's total operating expenses increased by 16.6% year-over-year, from $178.28M to $207.8M.
What is the long-term trend for Cytokinetics's total operating expenses?
Over 4 years (2021 to 2025), Cytokinetics's total operating expenses has grown at a 28.5% compound annual growth rate (CAGR), from $256.74M to $700.3M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about Cytokinetics's total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude